Browse > Article

Study on the Changes in the Blood Lipid Profile Levels of Patients with Metabolic Syndrome while Receiving Oriental Medicine Treatments for Various Diseases  

Kim, Dong-Woung (Department of Internal Medicine, College of Oriental Medicine, Wonkwang University)
Publication Information
Journal of Physiology & Pathology in Korean Medicine / v.23, no.2, 2009 , pp. 512-519 More about this Journal
Abstract
Among patients who visited each clinical department for oriental medical treatments, anthropometric measurement, blood pressure, fasting blood glucose and blood lipid profile level were measured at their first initial visit. 55 subject patients who were diagnosed as having metabolic syndrome and 150 mg/dL or more of triglyceride were selected as subjects whose fasting blood glucose, triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol were measured after fasting. According to each patient's disease, the subject received treatments such as herb medicine, acupuncture, moxibustion, cupping therapy, physical therapy and rehabilitation therapy from each clinical department, and after an average of 4.10${\pm}$0.31 weeks, another test was performed yielding the following results. Serum triglyceride was 243.72${\pm}$13.05 mg/dL before the oriental medical treatment and 188.11${\pm}$12.17 mg/dL after the treatment where although it continued to show an abnormal value even after the treatment, there was statistically significant decrease compared to pre treatment(P<0.05). Serum total cholesterol was 207.50${\pm}$5.89 mg/dL before the oriental medical treatment and 192.37${\pm}$5.53 mg/dL after the treatment which was statistically insignificant compared to pre treatment(P>0.05). Serum HDL cholesterol was 51.19${\pm}$3.95 mg/dL before the oriental medical treatment and increased to 52.53${\pm}$1.49 mg/dL after the treatment although it was statistically insignificant compared to pre treatment(P>0.05). Serum LDL cholesterol was 110.66${\pm}$5.86 mg/dL before the oriental medical treatment and decreased to 106.12${\pm}$4.82 mg/dL after the treatment although it was statistically insignificant compared to pre treatment(P>0.05). In regards to the change of triglyceride for each sex, it was 221.84${\pm}$14.01 mg/dL before the treatment and 187.00${\pm}$15.47 mg/dL after the treatment for men, and it was 271.50${\pm}$22.78 mg/dL and 189.53${\pm}$19.76 mg/dL respectively for women where even though men and women showed the decrease of 34.84${\pm}$12.79 mg/dL and 81.96${\pm}$20.01 mg/dL respectively, both men and women continue to show abnormal values after the treatments. However, there was statistically significant decrease compared to pre treatment(P<0.05). In regards to the change of total cholesterol for each sex, with 198.24${\pm}$7.60 mg/dL for men before the treatment and 188.93${\pm}$7.45 mg/dL after the treatment, values for both before and after the treatment were within the normal range where the change value was 9.30${\pm}$5.86 mg/dL and statistically insignificant(P>0.05). For women, it was 219.26${\pm}$8.87 mg/dL and 196.73${\pm}$8.43 mg/dL respectively for women where with 22.53${\pm}$7.60 mg/dL, it decreased to the normal level after the treatment, and there was a statistically significant decrease compared to pre treatment(P<0.05). With such results, serum triglyceride and cholesterol levels of patients who have been diagnosed as having metabolic syndrome were observed to decrease after the oriental medical treatment. Especially, for both men and women, abnormally high triglyceride level decreased while the effect of lipid profile improvement for women was more significant compared to men.
Keywords
metabolic syndrome; lipid profile; oriental medicine treatment;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Wilson, P.W.F., Kannel, W.B., Silbershartz, H., D'Agostino, R.B. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 159: 1104-1109, 1999   DOI   ScienceOn
2 Reven, G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37: 1595-1607, 1988   DOI   PUBMED   ScienceOn
3 H.S. Park, S.W. OH, J.H. Kang, Y.W. Park, J.M. Choi, Y.S. Kim, W.H. Choi, H.J. Yoo, Y.S. Kim. Prevalence and associated factors with metabolic syndrome in south korea-from the korean national health and nutrition examination survey 1998. Korean J of obesity(kor) 12(1):1-14, 2003
4 nternational Obesity Task Force. The Asia-Pacific perspective, Redefining obesity and its treatment. Western Pacific Region. 2000.
5 Hong, Y., Pedersen, N.L., Brismar, K., De Faire, U. Genetic and environmental architecture of the features of the insulin-resistance sydrome. Am J Hum Genet 60: 143-152, 1997   PUBMED
6 H.J. Lee, H.S. Kwon, Y.M. Park, H.N. Chun, Y.H. Choi, S.H. Ko, J.M. Lee, K.H. Yoon, B.Y. Cha, W.C. Lee, K.W. Lee, H.Y. Son, S.K. Kang, M.S. Ahn, J.M. Kang, D.S. Kim. Waist circumference as a risk factor for metabolic syndrome in Korean adult ; evaluation from 5 different criteria of metabolic syndrome(kor). J Kor Diabetes Assoc 29: 48-56, 2005
7 H.C. Jang, S. Yim, N.H. Jo. Metabolic syndrome -Korean Ansung and Ansan Cohort(KAAC) Study. Korean J Med 67 Supp(kor) 2: s528-532, 2004
8 Shepherd, J., Blauw, G.J., Murphy, M.B., Bollen, E.L., Buckley, B.M., Cobbe, S.M. Pravastartin in elderly individuals at risk of vascular disease(PROSPER): a randomized controlled trial. Lancet 360: 1623-1630, 2002   DOI   PUBMED   ScienceOn
9 Lakka, H.M., Laaksinen, D.E., Lakka, T.A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002   DOI   ScienceOn
10 Park, H.S., Kim, H.K., Park, K.S., Kim, S.Y., Park, Y.B., Cho, B.Y., Lee, K.L., Koh, C.S., Min, H.K., Kim, Y.I., Shin, Y.S., Paik, H.Y. Community based epidemiologic study on serum lipid profiles and their interaction with other atherosclerotic cardiovascular risk factors in Yonchon country. Korean J Lipidology(kor) 3: 191-203, 1993
11 Chen hanyang, Zhang Xiaoliang, Xiong Shangquan. Clinical Observation on the treatment of combined hyperlipidemia with Xiaotan Qingzhi Fang prescription and fluvastatin. Chin J GMCM May Vol 23(5):642-644, 2008
12 ACE position statement. Guidelindes for glycemic control. Endocr Pract 9(suppl. 1):7-19, 2003
13 Liu, S., Willett, W.C., Stampfer, M.J., Hu, F.B., Franz, M., Sampson, L., Hennekens, C.H., Manson, J.E. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 71: 1455-1461, 2000   DOI
14 Park, M.Y., Lee, K.S., Sung, M.K. Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in regulation to PPAP-$\alpha$, PPAP-$\gamma$, and LPL mRNA expression. Life Sci. 26: 3344-3354, 2005
15 Ricketts, M.L., Moore, D.D., Banz, W.J. et al. Molecular mechanism of action of the soy isoflavones includes activation of promiscuous nuclear receptors. J Nutr Biochem, 6: 321-330, 2005   DOI   PUBMED   ScienceOn
16 Grundy, S.M. A constellation of complications. The metabolic syndrome. Clin Cornerstone. 7: 36-45, 2005   DOI   ScienceOn
17 WHO(World Health Organization). Report of a WHO consultation of metabolic syndrome in definition, diagnosis, and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. World Health Organization, Department of Noncommunicable Disease Surveillance. Geneva, 1999
18 Einhorn, D., Reven, G.M., Cobin, R.H., Ford, E., Ganda, O.P., Handeksman, Y., Helliman, R., Jelinger, P.S., Kendall, D., Krauss, R.M., Neufeld, N.D., Petak, S.M., Rodbard, H.W., Seibel, J.A., Smith, D.A., Wilson, P.W. American college of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract, 9: 237-252, 2003
19 Alexander, C.M., Landsman, P.B., Teutsh, S.M., Haffner, S.M. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 52: 1210-1214, 2003   DOI   ScienceOn
20 Liese, A.D., Mayer-Davis, E.J., Tyroler, H.A., Davis, C.E., Keil, U., Schmit, M.I., Brancati, F.L., Heiss, G. Familial components of the multiple metabolic syndrome: The ARIC study. Diabetologia 40: 963-970, 1997   DOI   ScienceOn
21 Korea ministry for health, welfare and family affairs : From the korean national health and nutrition examination survey 1998. www.mw.go.kr
22 H.S. Park, H.C. Shin, B.S. Kim, K.Y. Lee, W.S. Choi, J.A. Shin, Y.D. Nam, S.P. Bae, K.S. Chun. Prevalence and associated factors of metabolic syndrome among adults in primary care. Korean J of obesity(kor) 12(2):108-123, 2003
23 Gordon, T., Castelli, W.P., Hjotland, M.C., Kannel, W.B., Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease. The ramnigham Study. Am J MED. 62(5):707-714, 1977   DOI   ScienceOn
24 Kou, W.R. The basic and clinic research of Xuezhikang. Chni Prescrip Drug(chin) 7: 52-57, 2005
25 Fan, C.L., Wo, X.D., Luo, Y. et al. Effect of curcumin on expression of human lymphocytes, Chin Phar J(chin) 40(13):980-983, 2005
26 Youl Lee Lym, Seung Wook Hwang, Hyun Jun Shim, Eun Hye Oh, Yoo Soo Chang, Be Long Cho. Prevalence and Risk Factors of the Metabolic Syndrome as Defined by NCEP-ATP III. J Korean Fam Med(kor), 24(2):135-143, 2003
27 K.H. Lee, J.C. Son, B.T. Kim, B.H. Choi, J.S. Hye, C.K. Cha, J.Y. Choi, Y.J. Lee, Y.H. Ahn. Non-HDL Cholesterol as a risk factor of metabolic syndrome in Korean women. Korean J of obesity(kor). 16(3):102-110, 2007
28 Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., Latho, K., Nissen, M. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24(4):683-689, 2001   DOI   ScienceOn
29 Executive Summary of the Third report of the National Cholesterol Education program(NCEP) Expert Panel on Detection, Evaluation, and treatment of high Blood cholesterol in Adults(Adult Treatment Pannel III). JAMA 28: 2486-2497, 2001
30 Castelli, W.P. The triglyceride issue: A view from framnigham. Am Heart J, 112(2):432-437, 1986   DOI   PUBMED   ScienceOn
31 Yan, J., Wo, X.D., Fan, C.L. et al. Effects of total flavonoids in hawthorn leaves on PPAR-$\gamma$, PPRE pathway regulatory system. Chni Pharm J(chin) 40(8):625-628, 2005
32 Korea National Statistical Office. Statistical analysis, Cause of death. www.nso.go.kr.
33 Cai, X.J. Observation of Huazhuo Jiangzhi Decoction in treating 80 patients with hyperlipidemia. Shaanxi J Tradit Chin Med(chin). 25(2):35-36, 2003